Additional User Fee Funding Will Boost Global Harmonization, Says FDA’s Torres

Recently passed legislation that includes higher medical device user fees will allow the US FDA to put more resources into establishing global harmonization standards with international partners.

International business concept with businessman and digital map superimposed on a city skyline background.
• Source: Shutterstock

During a panel on global regulatory convergence at the annual MedTech Conference in Boston, Melissa Torres of the US Food and Drug Administration’s device center discussed some of the implications of the Medical Device User Fee Amendment, or MDUFA V, on harmonizing international regulatory standards for medical devices.

Torres, associate director for international affairs at the FDA’s Center for Devices and Radiological Health (CDRH), said increased MDUFA V...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By 

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

Why EU Innovators Face Growing Barriers With EU Combination Product Regulation

 

Combination products are no longer fringe – they are the “new normal,” consultant Stephen O’Rourke told Medtech Insight. The EU has the expertise to handle the regulatory complexity, but only if connects the dots between silos. That’s the challenge, he said, and the opportunity.

UK MHRA Ready To Evolve Approach To In-House Manufactured Medtech

 
• By 

The UK device regulator wants to align health institution device exemptions with its evolving policy of agile regulation of medtech in the British market. It asks stakeholders to complete a survey by Sept. 15.

FDA Panel Supports Dermal Fillers For Décolletage Use

 
• By 

An FDA panel has endorsed the use of dermal fillers for décolletage, but warned of patient safety concerns. The filler can cause complications with future imaging and pregnancy or breastfeeding, panelists said. Regulatory measures and patient studies are recommended for better outcomes.

More from Policy & Regulation

Why EU Innovators Face Growing Barriers With EU Combination Product Regulation

 

Combination products are no longer fringe – they are the “new normal,” consultant Stephen O’Rourke told Medtech Insight. The EU has the expertise to handle the regulatory complexity, but only if connects the dots between silos. That’s the challenge, he said, and the opportunity.

NeuroOne Prepares To Launch Trigeminal Nerve Ablation System

 
• By 

The US FDA has cleared NeuroOne's OneRF trigeminal nerve ablation system for the treatment of trigeminal neuralgia. This minimally invasive method utilizes radio frequency energy to alleviate pain, offering an alternative to traditional medications and surgeries. A fall commercial launch is planned.

Warning Letters - July 2025

The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.